Source comparison
CJC-1295 No DAC & Ipamorelin: Research Concentration Comparison
CJC-1295 no DAC 5mg lyophilized 2.5mL bacteriostatic water 2mg/mL 100–300mcg per 0.05–0.15mL 28 days post-reconstitution Optimal balance between stability and dosing accuracy for typical GH secretagogue research protocols. Aggregation risk minimal at this conc
This comparison does not assign a generated winner or score.
- CJC-1295 no DAC
- 5mg lyophilized
- 2.5mL bacteriostatic water
- 2mg/mL
- 100–300mcg per 0.05–0.15mL
- 28 days post-reconstitution
- Optimal balance between stability and dosing accuracy for typical GH secretagogue research protocols. Aggregation risk minimal at this concentration
- Ipamorelin
- 2mL bacteriostatic water
- 2.5mg/mL
- 200–500mcg per 0.08–0.2mL
- Preferred for protocols requiring precise low-dose titration. Higher concentrations (5mg/mL) increase vial efficiency but reduce measurement accuracy below 0.1mL
- CJC-1295 + Ipamorelin (combined vial)
- 5mg CJC + 5mg IPA
- 3mL bacteriostatic water
- 1.67mg/mL CJC, 1.67mg/mL IPA
- Typical ratio 1:2 or 1:3 CJC:IPA by dose
- 21 days post-reconstitution
- Co-administration simplifies dosing schedules but shortens stability window. Peptide interaction in solution accelerates degradation compared to separate vials